![]() Our legal team is well versed in all areas involved in defective drug litigation and have a long track record of great success on behalf of clients.We have managed to secure over $2 billion in compensation for our clients in just the past decade.Xeljanz lawsuits have yet to be consolidated into class actions or federal multidistrict litigation, but most likely will in the near future. Issue a recall of Xeljanz or safety warnings regarding the increased risks users face at higher doses.Promptly follow through on post-market studies to investigate the potential cardiovascular risks.Properly research the side effects of Xeljanz before selling the drug.Disclose adverse event reports of pulmonary embolism, deep vein thrombosis, stroke and other blood clots of patients on Xeljanz.Provide accurate side effect warnings for Xeljanz consumers and the medical community.Plaintiffs who have suffered severe side effects, such as PE, DVT, or wrongful death, are seeking compensation and will likely raise the following allegations, claiming that Pfizer failed to: Lawsuits against Xeljanz’s manufacturer, Pfizer, are currently being individually filed across the country. All reported adverse events related to Xeljanz can be found in the FDA Adverse Event Reporting System (FAERS). Additionally, there have been five fatalities out of the 63 reported cases of Deep vein thrombosis (DVT). Patients are warned by the FDA to seek emergency medical attention if they experience any of the below symptoms or signs of a blood clot while taking Xeljanz:Īs of March 2019, there have been 109 cases of blood clots in the lungs, or Pulmonary Embolism (PE), 14 of which have resulted in death. Liver enzyme elevations and other laboratory abnormalities.Perforations of the stomach or intestines.Additional potentially severe side effects can be found on Xeljanz’s warning label: The FDA reported that the study indicates there is an increased risk of blood clots in the lungs and of death in patients taking 10 mg of Xeljanz or Xeljanz XR twice daily for rheumatoid arthritis. Results from an ongoing post-marketing safety study on Pfizer’s Xeljanz, prompted the FDA to issue a safety announcement on February 25, 2019. If you have been affected, contact the New York City Xeljanz lawsuit attorneys at Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. However, a recent clinical trial has concluded that a side effect of the drug may increase the risk of serious and potentially life-threatening blood clots in the lungs. ![]() The first member of a new class of drugs, called Xeljanz (tofacitinib), was approved to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |